NCT03150771View on ClinicalTrials.gov

Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

April 18, 2018

Study Completion Date

May 2, 2018

Conditions

Schizophrenia

Interventions

DRUG

Aripiprazole

Injection

Trial Locations (3)

72211

Woodland International Research Group, Little Rock

78754

Community Clinical Research Inc., Austin

92102

CNRI-San Diego, San Diego

All Listed Sponsors

collaborator

H. Lundbeck A/S

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT03150771 - Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia | Biotech Hunter | Biotech Hunter